A recent study indicates that darvadstrocel (DVS) outperformed standard of care (SOC) in treating complex perianal fistulas in Crohn’s disease, with patients experiencing shorter times to remission and longer intervals before relapse. Among 513 patients analyzed from both clinical trials and real-world data, a significantly higher proportion achieved clinical and patient-centric remission at 24 and 48 months with DVS compared to SOC. This integrated approach offers valuable insights into long-term treatment outcomes for this challenging condition.
Journal Article by Karki C, Hantsbarger G (…) Panés J et 4 al. in BMC Gastroenterol
© 2024. Takeda Pharmaceutical.